Diagnostics firm Diaceutics has teamed up with Lenovo and Intel for a collaboration that will apply artificial intelligence to improving patient outcomes, with a particular focus on cancer survivorship.

Diaceutics will leverage its proprietary database of patient testing data to see whether patients can be grouped according to diagnostic test information.

The Irish firm hopes that by doing so the data can help identify ways to improve diagnosis, treatment and outcomes for patients with similar characteristics.

Diaceutics’ CEO Peter Keeling (pictured above), said: “Artificial intelligence can make a very strong and positive impact on precision medicine and we are excited to be moving the boundaries with this highly innovative technology.

“We can now look at data in a novel way. No longer will we only be making decisions based on diagnostic data. Artificial intelligence allows us to look at the complete patient journey from initial testing and diagnosis, and on to the ultimate treatment.”

The collaboration would be a major step in his firm’s plans to help patients find “the right precision medicine at the right time”, he added.

The Lenovo/Intel system machine learning system being used in the collaboration will identify similarities and patterns within the testing data and highlight what is happening among groups of patients.

“Essentially, the organisation of this information could mean that at-risk patients can be identified, diagnosed and treated much faster,” Diaceutics said.

Digital inspiration for pharma on mobile, social media, strategy, best practice, regulations and more